Novel tumor suppressor SPRYD4 inhibits tumor progression in hepatocellular carcinoma by inducing apoptotic cell death
Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-associated deaths worldwide. Although recent studies have proposed different biomarkers for HCC progression and therapy resistance, a better understanding of the molecular mechanisms underlying HCC progression and recurrence, as well as the identification of molecular markers with a higher diagnostic accuracy, are necessary for the development of more effective clinical management strategies. Here, we aimed to identify novel players in HCC progression.
SPRYD4 mRNA and protein expression analyses were carried out on a normal liver-derived cell line (HL-7702) and four HCC-derived cell lines (HepG2, SMMC7721, Huh-7, BEL-7402) using qRT-PCR and Western blotting, respectively. Cell proliferation Cell Counting Kit-8 (CCK-8) assays, protein expression analyses for apoptosis markers using Western blotting, and Caspase-Glo 3/7 apoptosis assays were carried out on the four HCC-derived cell lines. Expression comparison, functional annotation, gene set enrichment, correlation and survival analyses were carried out on patient data retrieved from the NCBI Gene module, the NCBI GEO database and the TCGA database.
Through a meta-analysis we found that the expression of SPRYD4 was downregulated in primary HCC tissues compared to non-tumor tissues. We also found that the expression of SPRYD4 was downregulated in HCC-derived cells compared to normal liver-derived cells. Subsequently, we found that the expression of SPRYD4 was inversely correlated with a gene signature associated with HCC cell proliferation. Exogenous SPRYD4 expression was found to inhibit HCC cell proliferation by inducing apoptotic cell death. We also found that SPRYD4 expression was associated with a good prognosis and that its expression became downregulated when HCCs progressed towards more aggressive stages and higher grades. Finally, we found that SPRYD4 expression may serve as a biomarker for a good overall and relapse-free survival in HCC patients.
Our data indicate that a decreased SPRYD4 expression may serve as an independent predictor for a poor prognosis in patients with HCC and that increased SPRYD4 expression may reduce HCC growth and progression through the induction of apoptotic cell death, thereby providing a potential therapeutic target.
KeywordsHepatocellular carcinoma SPRYD4 Tumor suppressor Tumor progression Apoptosis
This work was supported in part by the Science and Technology Innovation Team Project of Liupanshui Normal University (Grant # LPSSYKJTD201602), the key disciplines of Guizhou province of China (Grant # Qian Xuewei He word ZDXK (2014)24), the Liupanshui Key Laboratory for Research and Utilization of Characteristic Fruit Tree Resources (Grant # 52020-2017-02-03) and the Research Foundation for Advanced Talents of Liupanshui Normal University (Grant # LPSSYKYJJ201601).
Compliance with ethical standards
Conflict of interest
The authors declare no potential conflicts of interest.
- 1.US Cancer Statsitics [Internet]. N.C.I. NIH. https://www.cancer.gov/about-cancer/understanding/statistics Accessed 2 May 2018
- 2.J. Byam, J. Renz, J.M. Millis, Liver transplantation for hepatocellular carcinoma. Hepatobiliary Surg. Nutr. 2, 22–30 (2013)Google Scholar
- 3.F. Bravi, C. Bosetti, A. Tavani, S. Gallus, C. La Vecchia, Coffee reduces risk for hepatocellular carcinoma: An updated meta-analysis. Clin. Gastroenterol. Hepatol. 11 e1411, 1413–1421 (2013)Google Scholar
- 7.M. Morimoto, K. Numata, A. Nozaki, M. Kondo, S. Moriya, M. Taguri, S. Morita, M. Konno, A. Sugo, E. Miyajima, S. Maeda, K. Tanaka, Novel Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein: A biomarker of hepatocellular carcinoma recurrence in patients with low alpha-fetoprotein concentrations. Int. J. Clin. Oncol. 17, 373–379 (2012)CrossRefGoogle Scholar
- 18.U. Raza, O. Saatci, S. Uhlmann, S.A. Ansari, E. Eyupoglu, E. Yurdusev, M. Mutlu, P.G. Ersan, M.K. Altundag, J.D. Zhang, H.T. Dogan, G. Guler, O. Sahin, The miR-644a/CTBP1/p53 axis suppresses drug resistance by simultaneous inhibition of cell survival and epithelial-mesenchymal transition in breast cancer. Oncotarget 7, 49859–49877 (2016)Google Scholar
- 19.M. Mutlu, O. Saatci, S.A. Ansari, E. Yurdusev, H. Shehwana, O. Konu, U. Raza, O. Sahin, miR-564 acts as a dual inhibitor of PI3K and MAPK signaling networks and inhibits proliferation and invasion in breast cancer. Sci. Rep. 6(32541) (2016)Google Scholar
- 20.J. Chaisaingmongkol, A Budhu, H Dang, S Rabibhadana, B Pupacdi, SM Kwon, M Forgues, Y Pomyen, V Bhudhisawasdi, N Lertprasertsuke, A Chotirosniramit, C Pairojkul, CU Auewarakul, T Sricharunrat, K Phornphutkul, S Sangrajrang, M Cam, P He, SM Hewitt, K Ylaya, X Wu, JB Andersen, SS Thorgeirsson, JJ Waterfall, YJ Zhu, J Walling, HS Stevenson, D Edelman, PS Meltzer, CA Loffredo, N Hama, T Shibata, RH Wiltrout, CC Harris, C Mahidol, M Ruchirawat, XW Wang and T-L Consortium, Common molecular subtypes among Asian hepatocellular carcinoma and cholangiocarcinoma Cancer Cell 32, 57–70 e53 (2017)Google Scholar
- 21.O.V. Grinchuk, S.P. Yenamandra, R. Iyer, M. Singh, H.K. Lee, K.H. Lim, P.K. Chow, V.A. Kuznetsov, Tumor-adjacent tissue co-expression profile analysis reveals pro-oncogenic ribosomal gene signature for prognosis of resectable hepatocellular carcinoma. Mol. Oncol. 12, 89–113 (2018)CrossRefGoogle Scholar
- 23.Y. Hoshida, A. Villanueva, A. Sangiovanni, M. Sole, C. Hur, K.L. Andersson, R.T. Chung, J. Gould, K. Kojima, S. Gupta, B. Taylor, A. Crenshaw, S. Gabriel, B. Minguez, M. Iavarone, S.L. Friedman, M. Colombo, J.M. Llovet, T.R. Golub, Prognostic gene expression signature for patients with hepatitis C-related early-stage cirrhosis. Gastroenterology 144, 1024–1030 (2013)CrossRefGoogle Scholar
- 26.C. Desmedt, A. Di Leo, E. de Azambuja, D. Larsimont, B. Haibe-Kains, J. Selleslags, S. Delaloge, C. Duhem, J.P. Kains, B. Carly, M. Maerevoet, A. Vindevoghel, G. Rouas, F. Lallemand, V. Durbecq, F. Cardoso, R. Salgado, R. Rovere, G. Bontempi, S. Michiels, M. Buyse, J.M. Nogaret, Y. Qi, F. Symmans, L. Pusztai, V. D'Hondt, M. Piccart-Gebhart, C. Sotiriou, Multifactorial approach to predicting resistance to anthracyclines. J. Clin. Oncol. 29, 1578–1586 (2011)CrossRefGoogle Scholar
- 28.B. Minguez, Y. Hoshida, A. Villanueva, S. Toffanin, L. Cabellos, S. Thung, J. Mandeli, D. Sia, C. April, J.B. Fan, A. Lachenmayer, R. Savic, S. Roayaie, V. Mazzaferro, J. Bruix, M. Schwartz, S.L. Friedman, J.M. Llovet, Gene-expression signature of vascular invasion in hepatocellular carcinoma. J. Hepatol. 55, 1325–1331 (2011)CrossRefGoogle Scholar
- 29.E.K. Tung, C.K. Mak, S. Fatima, R.C. Lo, H. Zhao, C. Zhang, H. Dai, R.T. Poon, M.F. Yuen, C.L. Lai, J.J. Li, J.M. Luk, I.O. Ng, Clinicopathological and prognostic significance of serum and tissue Dickkopf-1 levels in human hepatocellular carcinoma. Liver Int. 31, 1494–1504 (2011)CrossRefGoogle Scholar
- 32.J.H. Kim, B.H. Sohn, H.S. Lee, S.B. Kim, J.E. Yoo, Y.Y. Park, W. Jeong, S.S. Lee, E.S. Park, A. Kaseb, B.H. Kim, W.B. Kim, J.E. Yeon, K.S. Byun, I.S. Chu, S.S. Kim, X.W. Wang, S.S. Thorgeirsson, J.M. Luk, K.J. Kang, J. Heo, Y.N. Park, J.S. Lee, Genomic predictors for recurrence patterns of hepatocellular carcinoma: Model derivation and validation. PLoS Med. 11, e1001770 (2014)CrossRefGoogle Scholar
- 33.R.A. Busuttil, J. George, R.W. Tothill, K. Ioculano, A. Kowalczyk, C. Mitchell, S. Lade, P. Tan, I. Haviv, A. Boussioutas, A signature predicting poor prognosis in gastric and ovarian cancer represents a coordinated macrophage and stromal response. Clin. Cancer Res. 20, 2761–2772 (2014)CrossRefGoogle Scholar
- 34.E. Villa, R. Critelli, B. Lei, G. Marzocchi, C. Camma, G. Giannelli, P. Pontisso, G. Cabibbo, M. Enea, S. Colopi, C. Caporali, T. Pollicino, F. Milosa, A. Karampatou, P. Todesca, E. Bertolini, L. Maccio, M.L. Martinez-Chantar, E. Turola, M. Del Buono, N. De Maria, S. Ballestri, F. Schepis, P. Loria, G. Enrico Gerunda, L. Losi, U. Cillo, Neoangiogenesis-related genes are hallmarks of fast-growing hepatocellular carcinomas and worst survival. Results from a prospective study. Gut 65, 861–869 (2016)CrossRefGoogle Scholar
- 35.M. Melis, G. Diaz, D.E. Kleiner, F. Zamboni, J. Kabat, J. Lai, G. Mogavero, A. Tice, R.E. Engle, S. Becker, C.R. Brown, J.C. Hanson, J. Rodriguez-Canales, M. Emmert-Buck, S. Govindarajan, M. Kew, P. Farci, Viral expression and molecular profiling in liver tissue versus microdissected hepatocytes in hepatitis B virus-associated hepatocellular carcinoma. J. Transl. Med. 12, 230 (2014)CrossRefGoogle Scholar
- 36.Y. Murakami, S. Kubo, A. Tamori, S. Itami, E. Kawamura, K. Iwaisako, K. Ikeda, N. Kawada, T. Ochiya, Y.H. Taguchi, Comprehensive analysis of transcriptome and metabolome analysis in intrahepatic cholangiocarcinoma and hepatocellular carcinoma. Sci. Rep. 5, 16294 (2015)Google Scholar
- 38.K. Schulze, S. Imbeaud, E. Letouze, L.B. Alexandrov, J. Calderaro, S. Rebouissou, G. Couchy, C. Meiller, J. Shinde, F. Soysouvanh, A.L. Calatayud, R. Pinyol, L. Pelletier, C. Balabaud, A. Laurent, J.F. Blanc, V. Mazzaferro, F. Calvo, A. Villanueva, J.C. Nault, P. Bioulac-Sage, M.R. Stratton, J.M. Llovet, J. Zucman-Rossi, Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. Nat. Genet. 47, 505–511 (2015)CrossRefGoogle Scholar
- 39.O. Miltiadous, D. Sia, Y. Hoshida, M.I. Fiel, A.N. Harrington, S.N. Thung, P.S. Tan, H. Dong, K. Revill, C.Y. Chang, S. Roayaie, T.J. Byrne, V. Mazzaferro, J. Rakela, S. Florman, M. Schwartz, J.M. Llovet, Progenitor cell markers predict outcome of patients with hepatocellular carcinoma beyond Milan criteria undergoing liver transplantation. J. Hepatol. 63, 1368–1377 (2015)CrossRefGoogle Scholar
- 40.K.M. Lisowska, M. Olbryt, V. Dudaladava, J. Pamula-Pilat, K. Kujawa, E. Grzybowska, M. Jarzab, S. Student, I.K. Rzepecka, B. Jarzab, J. Kupryjanczyk, Gene expression analysis in ovarian cancer - faults and hints from DNA microarray study. Front. Oncol. 4, 6 (2014)Google Scholar
- 44.S. Udali, P. Guarini, A. Ruzzenente, A. Ferrarini, A. Guglielmi, V. Lotto, P. Tononi, P. Pattini, S. Moruzzi, T. Campagnaro, S. Conci, O. Olivieri, R. Corrocher, M. Delledonne, S.W. Choi, S. Friso, DNA methylation and gene expression profiles show novel regulatory pathways in hepatocellular carcinoma. Clin. Epigenetics 7, 43 (2015)CrossRefGoogle Scholar
- 45.M. Grinberg, R.M. Stober, K. Edlund, E. Rempel, P. Godoy, R. Reif, A. Widera, K. Madjar, W. Schmidt-Heck, R. Marchan, A. Sachinidis, D. Spitkovsky, J. Hescheler, H. Carmo, M.D. Arbo, B. van de Water, S. Wink, M. Vinken, V. Rogiers, S. Escher, B. Hardy, D. Mitic, G. Myatt, T. Waldmann, A. Mardinoglu, G. Damm, D. Seehofer, A. Nussler, T.S. Weiss, A. Oberemm, A. Lampen, M.M. Schaap, M. Luijten, H. van Steeg, W.E. Thasler, J.C. Kleinjans, R.H. Stierum, M. Leist, J. Rahnenfuhrer, J.G. Hengstler, Toxicogenomics directory of chemically exposed human hepatocytes. Arch. Toxicol. 88, 2261–2287 (2014)CrossRefGoogle Scholar
- 47.R. Tsunedomi, Y. Ogawa, N. Iizuka, K. Sakamoto, T. Tamesa, T. Moribe, M. Oka, The assessment of methylated BASP1 and SRD5A2 levels in the detection of early hepatocellular carcinoma. Int. J. Oncol. 36, 205–212 (2010)Google Scholar
- 48.H. Sun, J. Song, C. Weng, J. Xu, M. Huang, Q. Huang, R. Sun, W. Xiao, C. Sun, Association of decreased expression of the macrophage scavenger receptor MARCO with tumor progression and poor prognosis in human hepatocellular carcinoma. J. Gastroenterol. Hepatol. 32, 1107–1114 (2017)CrossRefGoogle Scholar
- 50.S. Boyault, D.S. Rickman, A. de Reynies, C. Balabaud, S. Rebouissou, E. Jeannot, A. Herault, J. Saric, J. Belghiti, D. Franco, P. Bioulac-Sage, P. Laurent-Puig, J. Zucman-Rossi, Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology 45, 42–52 (2007)CrossRefGoogle Scholar